Seguir
Catharina M.L. Zegers
Catharina M.L. Zegers
Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology
Dirección de correo verificada de maastro.nl
Título
Citado por
Citado por
Año
Radiomics: extracting more information from medical images using advanced feature analysis
P Lambin, E Rios-Velazquez, R Leijenaar, S Carvalho, ...
European journal of cancer 48 (4), 441-446, 2012
49022012
Rapid Learning health care in oncology’–an approach towards decision support systems enabling customised radiotherapy
P Lambin, E Roelofs, B Reymen, ER Velazquez, J Buijsen, CML Zegers, ...
Radiotherapy and Oncology 109 (1), 159-164, 2013
2172013
A comparative study of the hypoxia PET tracers [18F] HX4,[18F] FAZA, and [18F] FMISO in a preclinical tumor model
SGJA Peeters, CML Zegers, NG Lieuwes, W van Elmpt, J Eriksson, ...
International Journal of Radiation Oncology* Biology* Physics 91 (2), 351-359, 2015
1962015
Decision support systems for personalized and participative radiation oncology
P Lambin, J Zindler, BGL Vanneste, L Van De Voorde, D Eekers, ...
Advanced drug delivery reviews 109, 131-153, 2017
1482017
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
SGJA Peeters, CML Zegers, R Biemans, NG Lieuwes, ...
Clinical cancer research 21 (13), 2984-2992, 2015
1202015
In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging
CML Zegers, W Van Elmpt, B Reymen, AJG Even, EGC Troost, MC Öllers, ...
Clinical Cancer Research 20 (24), 6389-6397, 2014
1062014
Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects
CML Zegers, NH Rekers, DHF Quaden, NG Lieuwes, A Yaromina, ...
Clinical cancer research 21 (5), 1151-1160, 2015
1032015
Hypoxia imaging with [18F] HX4 PET in NSCLC patients: Defining optimal imaging parameters
CML Zegers, W van Elmpt, R Wierts, B Reymen, H Sharifi, MC Öllers, ...
Radiotherapy and Oncology, 2013
1002013
Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion
W van Elmpt, CML Zegers, B Reymen, AJG Even, AMC Dingemans, ...
European journal of nuclear medicine and molecular imaging 43, 240-248, 2016
862016
PET-based dose painting in non-small cell lung cancer: comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes
AJG Even, J van der Stoep, CML Zegers, B Reymen, EGC Troost, ...
Radiotherapy and Oncology 116 (2), 281-286, 2015
822015
Comparison of [18F]-FMISO,[18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia–a simulation study
LJ Wack, D Mönnich, W van Elmpt, CML Zegers, EGC Troost, D Zips, ...
Acta Oncologica, 1-8, 2015
792015
Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine
P Lambin, J Zindler, B Vanneste, L Van De Voorde, M Jacobs, D Eekers, ...
Acta Oncologica 54 (9), 1289-1300, 2015
732015
Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial
CML Zegers, W van Elmpt, K Szardenings, H Kolb, A Waxman, ...
European journal of nuclear medicine and molecular imaging 42, 1840-1849, 2015
722015
Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer
CML Zegers, FJP Hoebers, W van Elmpt, JA Bons, MC Öllers, EGC Troost, ...
European journal of nuclear medicine and molecular imaging 43, 2139-2146, 2016
682016
New ways to image and target tumour hypoxia and its molecular responses
LJ Dubois, R Niemans, SJA van Kuijk, KM Panth, NK Parvathaneni, ...
Radiotherapy and Oncology 116 (3), 352-357, 2015
612015
Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles
SG Peeters, CM Zegers, A Yaromina, W Van Elmpt, L Dubois, P Lambin
QJ Nucl Med Mol Imaging 59 (1), 39-57, 2015
572015
Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach
AJG Even, O Hamming-Vrieze, W van Elmpt, VJL Winnepenninckx, ...
Oncotarget 8 (3), 3870, 2017
562017
Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on …
AB Stillebroer, CML Zegers, OC Boerman, E Oosterwijk, PFA Mulders, ...
Journal of Nuclear Medicine 53 (1), 82-89, 2012
502012
Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer
W van Elmpt, M Das, M Hüllner, H Sharifi, CML Zegers, B Reymen, ...
Radiotherapy and Oncology 109 (1), 65-70, 2013
422013
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
NH Rekers, V Olivo Pimentel, A Yaromina, NG Lieuwes, R Biemans, ...
Oncoimmunology 7 (4), e1414119, 2018
412018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20